Fig. 1: IAP antagonists have rapid and potent on target activity in prostate cancer cell lines. | Cell Death & Disease

Fig. 1: IAP antagonists have rapid and potent on target activity in prostate cancer cell lines.

From: Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists

Fig. 1

a Western blot analysis of basal expression of cIAP1, cIAP2, XIAP, FLIP(L), FLIP(S), Procaspase-8, RIPK1, FADD, Procaspase-3 and β-actin in PC3, DU145 and VCaP cell lines. b Flow cytometric analysis of basal cell surface expression of TNFR1 in PC3, DU145 and VCaP cell lines compared to an IgG isotype control. c Western blot of cIAP1, cIAP2 and XIAP expression following treatment with 0, 10, 1, 0.1, 0.1, 0.01 and 0.001 μM TL32711 in PC3, DU145 and VCaP cell lines for 24 h. d Western Blot of cIAP1, cIAP2, and XIAP expression following 1, 3, 6, 12 and 24 h treatment with a clinically-achievable dose of 1 μM TL32711 in PC3 and DU145 cells. e Western blot analysis of cIAP1, cIAP2 and XIAP expression following treatment with 0, 10, 1, 0.1, 0.1, 0.01 and 0.001 μM ASTX660 in PC3, and DU145 cell lines for 24 h. f Western Blot of cIAP1, cIAP2, and XIAP expression following 1, 3, 6, 12 and 24 h treatment with 1 µM ASTX660 in PC3 and DU145 cell lines

Back to article page